<DOC>
	<DOCNO>NCT02782858</DOCNO>
	<brief_summary>The humanised IgG4 monoclonal antibody GNbAC1 target envelope protein ( Env ) human endogenous multiple sclerosis-associated retrovirus ( HERV-W MSRV ) , may play critical role multiple sclerosis ( MS ) . This study evaluate effect MRI lesions parameter , safety pharmacokinetics GNbAC1 patient relapse remit multiple sclerosis .</brief_summary>
	<brief_title>Clinical Trial Assessing HERV-W Env Antagonist GNbAC1 Efficacy MS</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<criteria>Main For male female reproductive potential , use reliable mean contraception ; RRMS accord 2010 revise McDonald criterion ; Disease activity characterise least one document relapse within last 12 month /or least one Gdenhancing T1 lesion selection evidence within last 3 month ; EDSS score &lt; 6.0 . Main Patients suffer Secondary Progressive MS Primary Progressive MS screening ; Pregnant nursing woman .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>Multiple Sclerosis Relapsing-Remitting</keyword>
	<keyword>GNbAC1</keyword>
	<keyword>MRI</keyword>
	<keyword>Monoclonal antibody</keyword>
	<keyword>Multiple Sclerosis associate retrovirus MSRV</keyword>
	<keyword>MS</keyword>
	<keyword>RRMS</keyword>
	<keyword>HERV-W</keyword>
</DOC>